APGE (Apogee Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

APGE (Apogee Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

APGEApogee Therapeutics, Inc.

Mkt Cap$4B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)$0

EPS (TTM)-$4.22

Free Cash Flow (TTM)-$233M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$13M
Q2 23	$0	$0	-$19M
Q3 23	$0	$0	-$24M
Q4 23	$0	$0	-$37M
Q1 24	$0	$0	-$38M
Q2 24	$0	$0	-$44M
Q3 24	$0	$0	-$59M
Q4 24	$0	$0	-$76M
Q1 25	$0	$0	-$63M
Q2 25	$0	$0	-$73M
Q3 25	$0	-$400K	-$71M
Q4 25	$0	$400K	-$78M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$11M	-$11M
Q2 23	-$15M	-$15M
Q3 23	-$20M	-$20M
Q4 23	-$30M	-$30M
Q1 24	-$32M	-$32M
Q2 24	-$29M	-$29M
Q3 24	-$43M	-$43M
Q4 24	-$68M	-$68M
Q1 25	-$48M	-$53M
Q2 25	-$62M	-$63M
Q3 25	-$54M	-$54M
Q4 25	-$63M	-$63M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$167K
Q1 24	$351K
Q2 24	$51K
Q3 24	$751K
Q4 24	$1K
Q1 25	$4M
Q2 25	$768K
Q3 25	$0
Q4 25	$62K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+194.0%
Q2 23	—	+939.9%
Q3 23	—	+131.3%
Q4 23	—	+163.5%
Q1 24	—	+201.6%
Q2 24	—	+133.6%
Q3 24	—	+141.5%
Q4 24	—	+104.2%
Q1 25	—	+65.3%
Q2 25	—	+65.8%
Q3 25	—	+21.5%
Q4 25	—	+2.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$1M	—
Q2 23	$1M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$4M	—
Q2 24	$6M	—
Q3 24	$6M	—
Q4 24	$8M	—
Q1 25	$11M	—
Q2 25	$11M	—
Q3 25	$12M	—
Q4 25	$12M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$8M	$4M
Q2 23	$14M	$5M
Q3 23	$17M	$7M
Q4 23	$29M	$8M
Q1 24	$29M	$9M
Q2 24	$33M	$11M
Q3 24	$46M	$13M
Q4 24	$60M	$16M
Q1 25	$46M	$17M
Q2 25	$56M	$17M
Q3 25	$54M	$17M
Q4 25	$58M	$20M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$141M	$0	$141M
Q2 23	$125M	$0	$125M
Q3 23	$188M	$235M	$423M
Q4 23	$118M	$277M	$395M
Q1 24	$485M	$331M	$816M
Q2 24	$307M	$369M	$676M
Q3 24	$119M	$407M	$526M
Q4 24	$142M	$379M	$521M
Q1 25	$107M	$406M	$513M
Q2 25	$124M	$381M	$505M
Q3 25	$108M	$419M	$527M
Q4 25	$132M	$599M	$730M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	51M	+0.0%
Q2 23	51M	+0.0%
Q3 23	51M	+0.0%
Q4 23	51M	-0.0%
Q1 24	50M	-0.9%
Q2 24	57M	+12.6%
Q3 24	57M	+0.5%
Q4 24	55M	-2.8%
Q1 25	58M	+5.4%
Q2 25	58M	+0.4%
Q3 25	59M	+0.6%
Q4 25	61M	+3.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 22	—	—
FY 23	$0	91
FY 24	$0	150K
FY 25	$0	150K